Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 27;15(1):127.
doi: 10.1186/s13014-020-01575-7.

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

Yosuke Takakusagi  1 , Hiroyuki Katoh  2 , Kio Kano  1 , Wataru Anno  1 , Keisuke Tsuchida  1 , Nobutaka Mizoguchi  1 , Itsuko Serizawa  1 , Daisaku Yoshida  1 , Tadashi Kamada  1
Affiliations

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

Yosuke Takakusagi et al. Radiat Oncol. .

Erratum in

Abstract

Background: Carbon-ion radiotherapy (CIRT) for prostate cancer was initiated at Kanagawa Cancer Center in 2015. The present study analyzed the preliminary clinical outcomes of CIRT for prostate cancer.

Methods: The clinical outcomes of 253 patients with prostate cancer who were treated with CIRT delivered using the spot scanning method between December 2015 and December 2017 were retrospectively analyzed. The irradiation dose was set at 51.6 Gy (relative biological effectiveness) delivered in 12 fractions over 3 weeks. Biochemical relapse was defined using the Phoenix definition. Toxicities were assessed according to CTCAE version 4.0.

Results: The median patient age was 70 (47-86) years. The median follow-up duration was 35.3 (4.1-52.9) months. According to the D'Amico classification system, 8, 88, and 157 patients were classified as having low, intermediate, and high risks, respectively. Androgen deprivation therapy was administered in 244 patients. The biochemical relapse-free rate in the low-, intermediate-, and high-risk groups at 3 years was 87.5, 88.0, and 97.5%, respectively (P = 0.036). Grade 2 acute urinary toxicity was observed in 12 (4.7%) patients. Grade 2 acute rectal toxicity was not observed. Grade 2 late urinary toxicity and grade 2 late rectal toxicity were observed in 17 (6.7%) and 3 patients (1.2%), respectively. Previous transurethral resection of the prostate was significantly associated with late grade 2 toxicity in univariate analysis. The predictive factor for late rectal toxicity was not detected.

Conclusion: The present study demonstrated that CIRT using the spot scanning method for prostate cancer produces favorable outcomes.

Keywords: Carbon-ion radiotherapy; Clinical outcome; Prostate cancer; Spot scanning method; Toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Biochemical relapse-free rate. The biochemical relapse-free rate in the low-, intermediate-, and high-risk groups at 3 years was 87.5, 88.0, and 97.5%, respectively (P = 0. 036)
Fig. 2
Fig. 2
Cumulative incidence rate of late rectal toxicities. The 3-year cumulative incidence rate of any-grade late rectal toxicity was 6.1%
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003;61:14–24. - PubMed
    1. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’amico risk classification of prostate cancer. Urology. 2007;70:931–935. - PubMed
    1. Sanguineti G, Cavey ML, Endres EJ, Brandon GG, Bayouth JE. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer? Int J Radiat Oncol Biol Phys. 2006;64:151–160. - PubMed
    1. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1–T3 adenocarcinoma of the prostate. Urology. 2000;55(1):85–90. - PubMed

Substances